Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Oragenics to Participate in the 2022 BioFlorida Annual Conference By: Oragenics, Inc. via Business Wire October 24, 2022 at 16:01 PM EDT Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami. Kim Murphy, President and CEO, will be participating on a panel titled “BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases” on Thursday, November 3 from 2:05 p.m. to 3:05 p.m. Panel: BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases Date: Thursday, November 3, 2022 Time: 2:05 p.m. Eastern Time Location: Hyatt Regency Miami Ms. Murphy will also be participating in BioFlorida’s one-on-one investor and business development meetings. Please contact LHA Investor Relations to schedule a meeting. About Oragenics, Inc. Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005965/en/Contacts Oragenics, Inc. Michael Sullivan, Chief Financial Officer 813-286-7900 msullivan@oragenics.com LHA Investor Relations Tirth T. Patel 212-201-6614 tpatel@lhai.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Oragenics to Participate in the 2022 BioFlorida Annual Conference By: Oragenics, Inc. via Business Wire October 24, 2022 at 16:01 PM EDT Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami. Kim Murphy, President and CEO, will be participating on a panel titled “BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases” on Thursday, November 3 from 2:05 p.m. to 3:05 p.m. Panel: BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases Date: Thursday, November 3, 2022 Time: 2:05 p.m. Eastern Time Location: Hyatt Regency Miami Ms. Murphy will also be participating in BioFlorida’s one-on-one investor and business development meetings. Please contact LHA Investor Relations to schedule a meeting. About Oragenics, Inc. Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005965/en/Contacts Oragenics, Inc. Michael Sullivan, Chief Financial Officer 813-286-7900 msullivan@oragenics.com LHA Investor Relations Tirth T. Patel 212-201-6614 tpatel@lhai.com
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami. Kim Murphy, President and CEO, will be participating on a panel titled “BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases” on Thursday, November 3 from 2:05 p.m. to 3:05 p.m. Panel: BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases Date: Thursday, November 3, 2022 Time: 2:05 p.m. Eastern Time Location: Hyatt Regency Miami Ms. Murphy will also be participating in BioFlorida’s one-on-one investor and business development meetings. Please contact LHA Investor Relations to schedule a meeting. About Oragenics, Inc. Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005965/en/
Oragenics, Inc. Michael Sullivan, Chief Financial Officer 813-286-7900 msullivan@oragenics.com LHA Investor Relations Tirth T. Patel 212-201-6614 tpatel@lhai.com